Home Product listing Zai Lab Announces Primary Listing on Main Board of Stock Exchange of Hong Kong Limited | New

Zai Lab Announces Primary Listing on Main Board of Stock Exchange of Hong Kong Limited | New

0

– First company to upgrade from secondary to primary status in Hong Kong

– Our dual primary listing on the Nasdaq and the Hong Kong Stock Exchange provides better access for investors

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative, patient-focused, commercial-stage global biopharmaceutical company, announced today today that it has completed its voluntary conversion from secondary listing status to primary listing on the main board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”). Zai Lab is now a listed company on both the Nasdaq and the Hong Kong Stock Exchange.

“As we execute our globalization and growth strategy, we are looking for new ways to attract potential investors who share Zai Lab’s vision to discover, develop and commercialize medicines to improve the lives of patients around the world. whole,” said Billy Cho, Zai’s chief financial officer. Laboratory. “We believe that our conversion from secondary to primary listing status will allow us to attract more potential investors to the Hong Kong Stock Exchange, helping us to broaden our shareholder base and improve the liquidity and profile of our securities. In addition, our ordinary shares listed on the Hong Kong Stock Exchange may soon be eligible for the China-Hong Kong Stock Connect, a link between mainland China and Hong Kong, providing Chinese investors with an increased ability to purchase and sell our securities in Hong Kong.”

“This is the first time a company has moved from a secondary listing to a primary listing on the Hong Kong Stock Exchange, and we look forward to deploying all additional resources to positively impact patient health. in China and around the world,” Cho added.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on delivering transformative medicines for the oncology, autoimmune diseases, infectious diseases and neurological disorders. patients in China and around the world. Our goal is to leverage our skills and resources to positively impact human health around the world.

For more information about Zai Lab, including information about our products, business activities and partnerships, research, or other events or developments, please visit www.zailaboratory.com or follow us on www.twitter.com/ZaiLab_Global.

Zai Lab Forward-Looking Statements

This press release contains forward-looking statements relating to Zai Lab’s voluntary conversion to a dual main listing on the Main Board of the Stock Exchange of Hong Kong Limited and its effective date, and the effects of such conversion. voluntary on society. investor and shareholder base and on the trading volume, liquidity and profile of the Company’s securities. These forward-looking statements can be identified by words such as “aims”, “anticipates”, “believes”, “could”, “estimates”, “expects”, “anticipates”, “target”, “has the intention to”, “could”, “plan”, “possible”, “potential”, “will”, “would” and other similar expressions. These statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors, including, but not limited to (1) our ability to successfully market and generate revenue from our approved products, (2) our ability to obtain financing for our operations and commercial initiatives, (3) the results of our clinical and preclinical development of our product candidates, (4) the content and timing of decisions made by the competent regulatory authorities regarding regulatory approvals of our product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on our business and general economic, regulatory and political conditions, (6) risks associated with conducting business in China, and (7) other factors identified in our most recent annual reports and quarterly reports and in other reports filed by us registered with the United States Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be taken to represent our views as of any date subsequent to the date of this press release.

Our filings with the SEC are available on our website at www.zailaboratory.com and on the SEC’s website at www.sec.gov.

For more information please contact:

Investor Relations: Lina Zhang

+86 136 8257 6943

[email protected]

Media: Danielle Halstrom / Xiaoyu Chen

+1 (215) 280-3898 / +86 185 0015 5011

[email protected] / [email protected]

Source: Zai Lab Limited

Copyright 2022 GlobeNewswire, Inc.